David DiGiusto

David DiGiusto has held a variety of roles in the healthcare industry since 1985. David began as a Graduate Student at National Jewish Health in 1985. David then worked as a Staff Scientist at Systemix from 1991 to 1995 and as a Scientist/Project Leader at Ribozyme Pharmaceuticals from 1995 to 1998. In 1998, they became a Research Professor of Virology at City of Hope, where they were responsible for blood cell-based translational research and Phase I/II clinical trials in oncology and infectious disease. In 2013, they took on the role of Instructor at Keck Graduate Institute. From 2015 to 2018, they served as Executive Director of Stem Cell and Cellular Therapeutics Operations at Stanford Health Care. David then moved to Semma Therapeutics as Chief Technical Officer, where they were responsible for the development and manufacturing of cell therapy products for clinical investigations. In 2020, they joined Vertex Pharmaceuticals as SVP of Cell & Gene Therapies Preclinical & Clinical Mfg - CMC. Most recently, in 2021, they began working at Resilience as CTO and SVP Stem Cells and Regenerative Medicine. In this role, they are investing time, resources, and capital to develop innovative and disruptive technology. David is also set to begin working as Chief Technology Officer at Garuda Therapeutics in 2022.

David DiGiusto obtained their Ph.D. in Microbiology and Immunology from the University of Colorado Anschutz Medical Campus between 1985 and 1990. David also obtained a BA in Molecular, Cellular and Developmental Biology from the University of Colorado Boulder between 1978 and 1982. In April 2022, they obtained a certification in "Having Difficult Conversations: A Guide for Managers" from LinkedIn.